BBOT · BridgeBio Oncology Therapeutics, Inc. · Executive Compensation
Market Cap
$221.28M
Shares
80.17M
Volume · Oct 21
12.89K
Avg daily vol (3M)
482.87K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Eli Wallace | Former President and Chief Executive Officer | $11,489,545 |
| Uneek Mehra | M.B.A. Former Chief Financial Officer | $4,555,625 |
| Yong Ben | M.D., M.B.A.^^ Chief Medical and Development Officer | $3,227,364 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Eli Wallace | Former President and Chief Executive Officer | $4,463,320 |
| Yong Ben | M.D., M.B.A.^^ Chief Medical and Development Officer | $1,455,587 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Frank P. McCormick, Ph.D., F.R.S., D. Sc. | Class I director | Appointed | 2026-06-22 |
| Peter Lebowitz, M.D., Ph.D. | Class I director | Appointed | 2026-06-22 |
| Michelle Doig | member of the Board of Directors of the Company | Resigned | 2026-06-22 |
| Pedro J. Beltran, Ph.D. | President and Chief Executive Officer | Appointed | 2026-04-29 |
| Pedro J. Beltran, Ph.D. | member of the Company's Board of Directors and as a Class III director | Appointed | 2026-04-29 |
| Eli Wallace, Ph.D. | member of the Company's Board of Directors and as a Class III director | Resigned | 2026-04-29 |
| Marc Cobo | principal accounting officer | Appointed | 2026-04-23 |
| Idan Elmelech | principal financial officer | Appointed | 2026-04-23 |
| Uneek Mehra | Chief Financial Officer | Resigned | 2026-04-23 |
| Neil Kumar, Ph.D. | Executive Chairman of the Board | Appointed | 2026-04-23 |
| Idan Elmelech | Chief Operating Officer | Appointed | 2026-04-23 |
| Pedro Beltran, Ph.D. | Class III director | Appointed | 2026-04-23 |
| Eli Wallace, Ph.D. | Class III director | Resigned | 2026-04-23 |
| Pedro Beltran, Ph.D. | President and Chief Executive Officer | Appointed | 2026-04-23 |
| Peter Lebowitz, M.D., Ph.D. | member of the Board | Appointed | 2026-03-26 |
| Yong Ben | Chief Medical and Development Officer | Appointed | 2025-08-13 |
| Pedro Beltran | Chief Scientific Officer | Appointed | 2025-08-13 |
| Eli Wallace | Chief Executive Officer | Appointed | 2025-08-13 |
| Yong Ben | Chief Medical and Development Officer | Appointed | 2025-08-13 |
| Uneek Mehra | Chief Financial Officer | Appointed | 2025-08-13 |
| Pedro Beltran | Chief Scientific Officer | Appointed | 2025-08-13 |
| Eli Wallace | Chief Executive Officer | Appointed | 2025-08-13 |
| Jake Bauer | Class III director | Appointed | 2025-08-13 |
| Raymond Kelleher | Class II director | Appointed | 2025-08-13 |
| Michelle Doig | Class I director | Appointed | 2025-08-13 |
Leadership
- Eli Wallace CEO, Board Member
- Pedro Beltran, Ph.D. CEO, Board Member
- Pedro J. Beltran, Ph.D. CEO, Board Member
- Neil Kumar, Ph.D. Chairman
- Idan Elmelech CFO, COO
- Uneek Mehra CFO
- Marc Cobo Chief Accounting Officer
- Albert A. Holman, III Board Member
- Bihua Chen Board Member
- Frank McCormick Board Member
- Frank P. McCormick Board Member
- Frank P. McCormick, Ph.D., F.R.S., D. Sc. Board Member
- Jake Bauer Board Member
- John Schmid Board Member
- Mark C. McKenna Board Member
- Michelle Doig Board Member
- Neil Kumar Board Member
- Peter Lebowitz Board Member
- Peter Lebowitz, M.D., Ph.D. Board Member
- Praveen Tipirneni Board Member
- Raymond Kelleher Board Member